CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 113 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $25,760,700 | +125.7% | 630,000 | +133.3% | 0.40% | +129.5% |
| Q1 2024 | $11,412,900 | -42.1% | 270,000 | -41.9% | 0.17% | -34.7% |
| Q4 2023 | $19,716,000 | +1620.3% | 465,000 | +785.7% | 0.26% | +1372.2% |
| Q3 2023 | $1,146,075 | -39.9% | 52,500 | -12.5% | 0.02% | -47.1% |
| Q2 2023 | $1,907,400 | +56.4% | 60,000 | +20.0% | 0.03% | +41.7% |
| Q1 2023 | $1,219,500 | -23.7% | 50,000 | -1.4% | 0.02% | -4.0% |
| Q4 2022 | $1,599,078 | -12.1% | 50,700 | -26.3% | 0.02% | 0.0% |
| Q2 2022 | $1,819,000 | -24.8% | 68,800 | -0.3% | 0.02% | -13.8% |
| Q1 2022 | $2,419,000 | -33.9% | 69,000 | -38.8% | 0.03% | -29.3% |
| Q4 2021 | $3,657,000 | +125.5% | 112,800 | +105.1% | 0.04% | +115.8% |
| Q3 2021 | $1,622,000 | – | 55,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |